

Accepted Manuscript

Title: A Systematic Review of Practice Guidelines and Recommendations for Discontinuation of Cholinesterase Inhibitors in Dementia

Author: Brenna N. Renn, Ali Abbas Asghar-Ali, Stephen Thielke, Angela Catic, Sharyl R. Martini, Brian G. Mitchell, Mark E. Kunik

PII: S1064-7481(17)30488-8
DOI: <https://doi.org/doi:10.1016/j.jagp.2017.09.027>
Reference: AMGP 941

To appear in: *The American Journal of Geriatric Psychiatry*

Received date: 8-6-2017
Revised date: 8-9-2017
Accepted date: 29-9-2017

Please cite this article as: Brenna N. Renn, Ali Abbas Asghar-Ali, Stephen Thielke, Angela Catic, Sharyl R. Martini, Brian G. Mitchell, Mark E. Kunik, A Systematic Review of Practice Guidelines and Recommendations for Discontinuation of Cholinesterase Inhibitors in Dementia, *The American Journal of Geriatric Psychiatry* (2017), <https://doi.org/doi:10.1016/j.jagp.2017.09.027>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Word Count: 4688 words, 75 refs.

**A Systematic Review of Practice Guidelines and Recommendations for
Discontinuation of Cholinesterase Inhibitors in Dementia**

Brenna N. Renn, PhD^{a, b, c}, Ali Abbas Asghar-Ali, MD^{b, d, e},
Stephen Thielke, MD, MSPH, MA^{c, f}, Angela Catic, MD^{d, e, g}, Sharyl R. Martini, MD, PhD^{d, h},
Brian G. Mitchell, PharmD^{b, d}, & Mark E. Kunik, MD, MPH^{a, b, d, e, i}

^a VA HSR&D Houston Center of Innovation, Michael E. DeBakey VA Medical Center,
Houston, TX

^b Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine,
Houston, TX

^c Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA

^d Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX

^e VA South Central Mental Illness Research, Education and Clinical Center, Houston, TX

^f Veterans Affairs (VA) Puget Sound Health Care System, Seattle, WA

^g Department of Medicine, Section of Geriatrics, Baylor College of Medicine, Houston, TX

^h Department of Neurology, Baylor College of Medicine, Houston, TX

ⁱ Department of Medicine, Section of Health Services Research, Baylor College of Medicine,
Houston, TX

Corresponding Author:

Mark E. Kunik, MD, MPH

2450 Holcombe Boulevard, Suite 01Y, Houston, TX 77021

Phone: (713) 794-8639

Fax: (713) 748-7359

Email: mkunik@bcm.edu

This research was partially supported by the US Department of Veterans Affairs (VA) HSR&D Houston Center for Innovations in Quality, Effectiveness and Safety (CIN# 13-413), Michael E. DeBakey VA Medical Center, Houston, TX, and by a training grant from the National Institutes of Health (T32MH073553-11). The views expressed reflect those of the authors and not necessarily the policy or position of the Department of Veterans Affairs, the US government, Baylor College of Medicine, or the University of Washington. None of these bodies played a role in study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.

Portions of this work were presented at the Annual Meeting of the American Association for Geriatric Psychiatry, held March 24-27, 2017 in Dallas, TX.

The authors report no financial conflicts of interest.

Keywords: Alzheimer's disease, cholinesterase inhibitor,
treatment, discontinuation, deprescribing

Download English Version:

<https://daneshyari.com/en/article/8680880>

Download Persian Version:

<https://daneshyari.com/article/8680880>

[Daneshyari.com](https://daneshyari.com)